Brief: BioXcel Therapeutics Enters Twelfth Amendment To Credit Agreement On August 10, 2026 - SEC Filing
11/08/2026 12:54
BRIEF-BioXcel Therapeutics Enters Twelfth Amendment To Credit Agreement On August 10, 2026 - SEC Filing Aug 11 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS - ENTERS TWELFTH AMENDMENT TO CREDIT AGREEMENT ON AUGUST 10, 2026 - SEC FILING
BIOXCEL THERAPEUTICS - REQUIRED TO ENTER AGREEMENTS BY AUGUST 21, 2026, TO REPAY OBLIGATIONS OR PURSUE ALTERNATIVE CAPITAL SOLUTIONS - SEC FILING
BIOXCEL THERAPEUTICS - LENDERS REDUCE MINIMUM LIQUIDITY COVENANT TO $3 MILLION FROM $6.25 MILLION - SEC FILING
Source text: [ID:n0001104659-26-093710]
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty